Payment overview · 2025
General Payments
$399.62
21 reported records · 10 companies
Healthcare provider profile · identity verified
Franklin W Waller, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBIA, MS · NPI 1497864607
Verified facts
What the public records show
CMS Open Payments records show Franklin W Waller, MD received $399.62 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $147.67 | 37.0% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.04 | 18.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.78 | 8.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.47 | 8.1% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $25.21 | 6.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.78 | 5.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.49 | 4.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.99 | 4.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.58 | 4.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.61 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $399.62 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $147.67 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $75.04 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.71 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $53.11 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $25.21 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
89 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 883 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 127 |
| Gabapentin | Gabapentin | 455 | 108 |
| Losartan Potassium | Losartan Potassium | 419 | 112 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 397 | 45 |
| Lisinopril | Lisinopril | 333 | 88 |
| Furosemide | Furosemide | 320 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 67 |
| Tizanidine Hcl | Tizanidine Hcl | 257 | 47 |
| Omeprazole | Omeprazole | 243 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 227 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 53 |
| Carvedilol | Carvedilol | 201 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 195 | 55 |
| Metformin Hcl | Metformin Hcl | 175 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 163 | 42 |
| Potassium Chloride | Potassium Chloride | 155 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 34 |
| Allopurinol | Allopurinol | 137 | 36 |
| Meloxicam | Meloxicam | 134 | 37 |
| Trazodone Hcl | Trazodone Hcl | 126 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 38 |
| Alprazolam | Alprazolam | 124 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 24 |
| Famotidine | Famotidine | 98 | 28 |
| Simvastatin | Simvastatin | 95 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 91 | 30 |
| Linzess | Linaclotide | 89 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 28 |
| Tramadol Hcl | Tramadol Hcl | 84 | 19 |
| Buspirone Hcl | Buspirone Hcl | 81 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 17 |
| Ezetimibe | Ezetimibe | 78 | 15 |
| Cefuroxime | Cefuroxime Axetil | 77 | 63 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 59 |
| Pregabalin | Pregabalin | 76 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 22 |
| Montelukast Sodium | Montelukast Sodium | 74 | 17 |
| Glimepiride | Glimepiride | 72 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 21 |
| Alendronate Sodium | Alendronate Sodium | 64 | 15 |
| Valsartan | Valsartan | 61 | 16 |
| Ozempic | Semaglutide | 57 | 15 |
| Promethazine Hcl | Promethazine Hcl | 56 | 12 |
| Ondansetron Odt | Ondansetron | 55 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 20 |
| Methylprednisolone | Methylprednisolone | 54 | 39 |
| Megestrol Acetate | Megestrol Acetate | 52 | 17 |
| Mupirocin | Mupirocin | 52 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 12 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Eliquis | Apixaban | 48 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 11 |
| Chlorthalidone | Chlorthalidone | 45 | 12 |
| Atenolol | Atenolol | 44 | suppressed |
| Lovastatin | Lovastatin | 43 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 30 |
| Sertraline Hcl | Sertraline Hcl | 41 | 13 |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 13 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Sucralfate | Sucralfate | 33 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 15 |
| Azithromycin | Azithromycin | 27 | 25 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 13 |
| Ibu | Ibuprofen | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 20 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | 14 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $399.62 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, DAYBUE, FARXIGA, GEMTESA, INTELLIS ADAPTIVESTIM, JARDIANCE, MOUNJARO, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error